[Erythromelalgia: Diagnosis and therapeutic approach].

Abstract

Erythromelalgia is a rare intermittent vascular acrosyndrome characterized by the combination of recurrent burning pain, warmth and redness of the extremities. It is considered in its primary form as an autosomal dominant neuropathy related to mutations of SCN9A, the encoding gene of a voltage-gated sodium channel subtype Nav1.7. Secondary erythromelalgia is associated with myeloproliferative disorders, drugs (bromocriptine, calcium channel blockers), or clinical conditions such as rheumatic diseases or viral infection. Primary familial erythromelalgia include genetics and sporadic forms associated with small fibers neuropathy. Aspirin is a useful treatment of erythromelagia associated with myeloproliferative disorders. Treatment of primary erythromelalgia is difficult, individualized, with sodium channel blockers such as lidocaine, carbamazepine and mexiletine.

• Authors: S Miranda, M Le Besnerais, V Langlois, Y Benhamou, H Lévesque
• Journal: La Revue de medecine interne (Rev Med Interne) Vol. 38 Issue 3 Pg. 176-180 (Mar 2017) ISSN: 1768-3122 [Electronic] France
• Vernacular Title: L’érythromélalgie : approche diagnostique et thérapeutique actuelle.
• PMID: 27639908 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Chemical References

• Calcium Channel Blockers
• Sodium Channel Blockers

Topics

• Calcium Channel Blockers (therapeutic use)
• Diagnostic Techniques and Procedures
• Erythromelalgia (classification, diagnosis, epidemiology, therapy)
• Humans
• Sodium Channel Blockers (therapeutic use)